Sponsors still put “El Salvador” on one regulatory Gantt with a single 30–60 day band. That is the mistake. A first-in-human (FIH) or early feasibility study (EFS) for a medical device in El Salvador runs as a CNEIS ethics vote plus an SRS clinical-investigation authorization. Putting the same Class III implantable on the Salvadoran market later is a DNM/SRS registro sanitario. Same clock language. Different petition, different importer, different success criterion.
If the board slide says “El Salvador approved in 30–60 days,” ask which file. Trial authorization is not a commercial registro. Confusing them delays first patient and later stalls commercial import.
Two files, one country
The Superintendencia de Regulación Sanitaria (SRS), established in August 2024 under the Ley de la Superintendencia de Regulación Sanitaria (7 August 2024), replaced the Dirección Nacional de Medicamentos (DNM) as El Salvador’s national sanitary authority. Ethics for clinical research sits with the Comité Nacional de Ética de la Investigación en Salud (CNEIS). Parallel SRS and CNEIS review is already published on the El Salvador clinical-trials hub as the reason that country page shows a 30–60 day study-startup band.
For a U.S.-based medtech sponsor, the practical split looks like this:
- Trial file: Spanish protocol package, investigator brochure, informed consent, CNEIS ethics package, SRS investigation authorization, investigational labeling, ISO 14155 monitoring plan, and the import story for units that will only be used in the study. The live step-by-step FIH guide already names the SRS-CNEIS-ES digital platform and the user manual issued 17 November 2025. Use that manual. Do not invent article numbers from CNEIS reforms you have not opened.
- Registro file: commercial sanitary registration through DNM/SRS for manufacture, import, storage, distribution, and promotion of a commercial device, with a Salvadoran party the authority will treat as responsible for that certificate — not a PI’s clinic stamp and not a named hospital that happens to have run FIH.
Hospital El Salvador appears on the public landscape as infrastructure. It is not a hospital bioaccess® operates, and it is not the commercial titular on a registro. Public San Salvador sites are sites. They are not the CRO and they are not the holder.
The same 30–60 day language also appears on the market-access hub for El Salvador commercial registration (experience-based). That is the punchline: identical band, different petition. Do not merge the two clocks into one Gantt bar labeled “El Salvador.”
What FDA reviewers will ask later
If the El Salvador FIH is meant to support a U.S. IDE or marketing file, design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States). That regulation expects GCP, independent ethics review, and a device comparable to the version you will put in front of FDA.
ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean SRS investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, and the CNEIS correspondence in one place from day one. Eligibility of foreign data under 812.28 is not a clearance prediction.
El Salvador is a lead FIH jurisdiction for bioaccess®, with Miami headquarters and a dollarized economy already published on the country hub. None of that converts a trial authorization into a selling license. Do not put a single “El Salvador clock” on the Gantt and call it done.
Import: investigational units are not the registro SKU
A commercial DNM/SRS registration number does not clear investigational kits. Do not put a cousin SKU’s registro on the airway bill “because the PI knows customs.” Name the trial importer before CNEIS stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational, with lot or serial traceability that matches the accountability log at the site.
After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy. The commercial registro track — when you actually need it — is a separate workstream with its own importer and its own holder.
Holder vs distributor (commercial track only)
When you later want Salvadoran market access, SRS will look for a local face on the sanitary registration: renewals, variations, labeling, and vigilance. A distributor who only sells stock is not automatically that holder. If the holder relationship breaks, the registro does not quietly follow the freight forwarder — you re-file.
That commercial conversation belongs on a separate workstream from the investigation calendar. Running them as one “El Salvador regulatory” workstream is how teams discover, mid-enrollment, that nobody can import the commercial launch SKU. The market-access hub already states that commercial registration is a second file. Keep it that way inside your own team.
One-page gate before first patient in El Salvador
Write these lines with owners and document IDs before you book site initiation:
- Authority map. SRS investigation plus CNEIS ethics for the study. DNM/SRS registro only if a parallel commercial file is truly in scope this year.
- Ethics + investigation sequence. Same protocol version and the same Spanish informed-consent text in both packages. Submit through the SRS-CNEIS-ES platform already named on the live FIH guide; use the 17 November 2025 user manual as the operational reference.
- Investigational importer. Legal name and the document that ties the shipment to the investigation authorization — not a commercial registro number.
- Device list. Every unit that will sit in the site accountability log, including accessories.
- ISO 14155 file owner. Who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
- Commercial holder (optional, separate). If launch is real, name the Salvadoran titular and keep that file off the FIH critical path until first patient is locked.
Where teams burn weeks
Three patterns show up repeatedly on El Salvador device files:
- One 30–60 day bar for both desks. Treating the published study-startup band and the experience-based commercial registration band as the same petition. They share clock language. They do not share a dossier.
- Registro number on investigational freight. Using a commercial DNM/SRS certificate for a predicate or related model to move FIH units. The investigational article is not that registered product.
- One Spanish translation for both desks. The informed-consent and brochure language for CNEIS and the investigation is not the commercial IFU SRS will later lock on a registro. Mixing them creates labeling debt on both tracks.
Fix the patterns on paper before translators start. Re-translation after first patient is a protocol amendment problem, not a word-processing problem. Sibling posts on the same split for other LATAM markets — including the CRO in El Salvador category page — already make the same point: trial and registro are not one Gantt.
Practical next step
This week, split the El Salvador slide into two columns: CNEIS/SRS investigation and DNM/SRS registro. If the same person owns both without two dossiers, two importers, and two success criteria, you do not have an El Salvador plan — you have a hope. bioaccess® runs FIH/EFS execution across Latin America, including El Salvador as a lead FIH jurisdiction from Miami, and holds LATAM registration/IOR work as a separate market-access track; treat El Salvador the same way inside your own team. Start from the clinical-trials hub for the investigation column and the market-access hub for the registro column — and do not collapse them because both say 30–60 days.